Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erwin Woff

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Clinical Nuclear Medicine|April 26, 2020
Colon Adenocarcinoma Associated With Clostridium Septicum Endophthalmitis Detected on 18F-FDG PET/CTNicolas Plouznikoff, Carlos Artigas, Erwin Woff, et al.
Clinical Nuclear Medicine|July 6, 2019
Incidental Detection of a Radiation-Induced Soft-Tissue Sarcoma on 68Ga-PSMA PET/CT in a Patient Previously Treated for Prostate CancerNicolas Plouznikoff, Erwin Woff, Carlos Artigas, et al.
European Journal of Case Reports in Internal Medicine|March 26, 2021
Sarcoidosis Versus Lymphoma?Lissandra Dal Lago, Julie Sarrand, Erwin Woff, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 10, 2019
Combining <sup>18</sup>F-FDG PET/CT-Based Metabolically Active Tumor Volume and Circulating Cell-Free DNA Significantly Improves Outcome Prediction in Chemorefractory Metastatic Colorectal CancerErwin Woff, Pashalina Kehagias, Caroline Vandeputte, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 1, 2018
Validation of Metabolically Active Tumor Volume and Total Lesion Glycolysis as 18F-FDG PET/CT–derived Prognostic Biomarkers in Chemorefractory Metastatic Colorectal CancerErwin Woff, Alain Hendlisz, Lieveke Ameye, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 27, 2025
The SCARLET trial: a prospective phase II study of somatostatin receptor imaging for potential radiotheranostic application in patients with relapsing and refractory multiple myelomaWendy Delbart, Ioannis Karfis, Marie Vercruyssen, et al.
EJNMMI Reports|July 27, 2025
First-in-human experience of radiopharmaceutical therapy with [<sup>177</sup>Lu]Lu-DOTATATE in patients with advanced multiple myelomaWendy Delbart, Marie Vercruyssen, Rachele Danieli, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 30, 2021
Combined Metabolically Active Tumor Volume and Early Metabolic Response Improve Outcome Prediction in Metastatic Colorectal CancerErwin Woff, Lisa Salvatore, Federica Marmorino, et al.
Clinical Nuclear Medicine|June 29, 2023
Tumor Volume on PSMA PET as a Prognostic Biomarker in Prostate Cancer Patients Treated With CabazitaxelQaid Ahmed Shagera, Ioannis Karfis, Spyridon Sideris, et al.
JCO Clinical Cancer Informatics|April 30, 2025
Development and Validation of an <sup>18</sup>F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography-Based Imaging Score to Predict 12-Week Life Expectancy in Advanced Chemorefractory Colorectal CancerZelda Paquier, Jennifer Dhont, Thomas Guiot, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Clinical Nuclear Medicine|April 26, 2020
Colon Adenocarcinoma Associated With Clostridium Septicum Endophthalmitis Detected on 18F-FDG PET/CTNicolas Plouznikoff, Carlos Artigas, Erwin Woff, et al.
Clinical Nuclear Medicine|July 6, 2019
Incidental Detection of a Radiation-Induced Soft-Tissue Sarcoma on 68Ga-PSMA PET/CT in a Patient Previously Treated for Prostate CancerNicolas Plouznikoff, Erwin Woff, Carlos Artigas, et al.
European Journal of Case Reports in Internal Medicine|March 26, 2021
Sarcoidosis Versus Lymphoma?Lissandra Dal Lago, Julie Sarrand, Erwin Woff, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 10, 2019
Combining <sup>18</sup>F-FDG PET/CT-Based Metabolically Active Tumor Volume and Circulating Cell-Free DNA Significantly Improves Outcome Prediction in Chemorefractory Metastatic Colorectal CancerErwin Woff, Pashalina Kehagias, Caroline Vandeputte, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 1, 2018
Validation of Metabolically Active Tumor Volume and Total Lesion Glycolysis as 18F-FDG PET/CT–derived Prognostic Biomarkers in Chemorefractory Metastatic Colorectal CancerErwin Woff, Alain Hendlisz, Lieveke Ameye, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 27, 2025
The SCARLET trial: a prospective phase II study of somatostatin receptor imaging for potential radiotheranostic application in patients with relapsing and refractory multiple myelomaWendy Delbart, Ioannis Karfis, Marie Vercruyssen, et al.
EJNMMI Reports|July 27, 2025
First-in-human experience of radiopharmaceutical therapy with [<sup>177</sup>Lu]Lu-DOTATATE in patients with advanced multiple myelomaWendy Delbart, Marie Vercruyssen, Rachele Danieli, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 30, 2021
Combined Metabolically Active Tumor Volume and Early Metabolic Response Improve Outcome Prediction in Metastatic Colorectal CancerErwin Woff, Lisa Salvatore, Federica Marmorino, et al.
Clinical Nuclear Medicine|June 29, 2023
Tumor Volume on PSMA PET as a Prognostic Biomarker in Prostate Cancer Patients Treated With CabazitaxelQaid Ahmed Shagera, Ioannis Karfis, Spyridon Sideris, et al.
JCO Clinical Cancer Informatics|April 30, 2025
Development and Validation of an <sup>18</sup>F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography-Based Imaging Score to Predict 12-Week Life Expectancy in Advanced Chemorefractory Colorectal CancerZelda Paquier, Jennifer Dhont, Thomas Guiot, et al.
Pageof 2